Aeolus Pharmaceuticals’ AEOL 10150 Protects Lungs From Fractionated Radiation; Reduces Angiogenesis And Inflammation
Aeolus Pharmaceuticals, Inc. (OTCBB: AOLS) reported data published in the peer-reviewed journal, Free Radical Research, show the Company's lead compound, AEOL 10150, provided statistically significant protection of the lungs of Fisher 344 rats exposed to fractionated radiation in a study led by Zeljko Vujaskovic, M.D. Ph.D. of Duke University.
(more...)
(more...)
